RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Swedish Orphan Biovitrum AB (publ) EBIT 2024

Swedish Orphan Biovitrum AB (publ) EBIT

5.36 B SEK

Swedish Orphan Biovitrum AB (publ) Dividend yield

Ticker

SOBI.ST

ISIN

SE0000872095

WKN

A0LA5K

In 2024, Swedish Orphan Biovitrum AB (publ)'s EBIT was 5.36 B SEK, a 14.52% increase from the 4.68 B SEK EBIT recorded in the previous year.

The Swedish Orphan Biovitrum AB (publ) EBIT history

YEAREBIT (undefined SEK)
2029e-
2028e10.36
2027e10.15
2026e9.98
2025e7.97
2024e5.36
20234.68
20224.52
20213.79
20204.46
20194.5
20183.13
20171.65
20161.13
20150.15
2014-0.33
2013-0.07
2012-0.02
2011-0.24
20100.08
20090.05
2008-0.04
20070.06
20060.05
20050.02
2004-0.27

Swedish Orphan Biovitrum AB (publ) Aktienanalyse

What does Swedish Orphan Biovitrum AB (publ) do?

Swedish Orphan Biovitrum AB (Sobi) is a Swedish biotechnology company specializing in rare diseases. It was founded in 1986 as Swedish Orphan International and renamed Swedish Orphan Biovitrum AB (Sobi) in 2007. Sobi is headquartered in Stockholm and is listed on NASDAQ OMX Stockholm. Its business model focuses on developing and marketing therapies for rare diseases with limited treatment options. Sobi operates in Europe, the Middle East, North Africa, and North America, collaborating closely with patient organizations and medical professionals to raise awareness of rare diseases and provide patients with access to important therapies. The company is divided into three business areas: Hemophilia, Inflammatory Diseases, and Genetic Diseases. Sobi offers medications for bleeding disorders, inflammatory diseases, and lysosomal storage diseases, among others. Some of its key products include Elocta and Alprolix for Hemophilia A and B, Kineret for autoinflammatory diseases, Synagis for respiratory syncytial virus (RSV) infections in children, Vimizim for mucopolysaccharidosis type IVA, and Orfadin for hereditary tyrosinemia type 1. In conclusion, Sobi is a leading biotechnology company dedicated to developing and marketing therapies for rare diseases, with a wide range of products in its portfolio. It collaborates with patient organizations and strives to improve the quality of life for patients with rare diseases. Swedish Orphan Biovitrum AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Swedish Orphan Biovitrum AB (publ)'s EBIT

Swedish Orphan Biovitrum AB (publ)'s Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Swedish Orphan Biovitrum AB (publ)'s EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Swedish Orphan Biovitrum AB (publ)'s EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Swedish Orphan Biovitrum AB (publ)’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Swedish Orphan Biovitrum AB (publ) Stock

How much did Swedish Orphan Biovitrum AB (publ) achieve in EBIT for the current year?

In the current year, Swedish Orphan Biovitrum AB (publ) has achieved an EBIT of 5.36 B SEK.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Swedish Orphan Biovitrum AB (publ).

How has the EBIT of Swedish Orphan Biovitrum AB (publ) developed in recent years?

The EBIT of Swedish Orphan Biovitrum AB (publ) has increased by 14.521% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Swedish Orphan Biovitrum AB (publ)?

The EBIT of Swedish Orphan Biovitrum AB (publ) is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Swedish Orphan Biovitrum AB (publ) pay?

Over the past 12 months, Swedish Orphan Biovitrum AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Swedish Orphan Biovitrum AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Swedish Orphan Biovitrum AB (publ)?

The current dividend yield of Swedish Orphan Biovitrum AB (publ) is .

When does Swedish Orphan Biovitrum AB (publ) pay dividends?

Swedish Orphan Biovitrum AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Swedish Orphan Biovitrum AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Swedish Orphan Biovitrum AB (publ) located?

Swedish Orphan Biovitrum AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Swedish Orphan Biovitrum AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Swedish Orphan Biovitrum AB (publ) from 5/28/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did Swedish Orphan Biovitrum AB (publ) pay the last dividend?

The last dividend was paid out on 5/28/2024.

What was the dividend of Swedish Orphan Biovitrum AB (publ) in the year 2023?

In the year 2023, Swedish Orphan Biovitrum AB (publ) distributed 0 SEK as dividends.

In which currency does Swedish Orphan Biovitrum AB (publ) pay out the dividend?

The dividends of Swedish Orphan Biovitrum AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Swedish Orphan Biovitrum AB (publ)

Our stock analysis for Swedish Orphan Biovitrum AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Swedish Orphan Biovitrum AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.